Novel oral anticoagulants for prophylaxis and treatment of venous thromboembolism: Part i (Factor Xa inhibitors)

Rohtesh S. Mehta

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations

Abstract

The quest for an ideal anticoagulant is ongoing. Oral agents that do not require blood level monitoring are presently undergoing taut scrutiny for efficacies and potential side effects, and would potentially soon revolutionize coagulation medicine. The first part of this article reviews oral Factor Xa inhibitors, such as rivaroxaban, apixaban, eribaxaban, edoxaban and YM150 - exploring the outcomes of major clinical trials for prophylaxis and treatment of venous thromboembolism - and also briefly outlining their pharmacological properties. The second part of the article (in a separate issue) will cover oral Factor IIa (thrombin), such as dabigatran and AZD0837 and oral Factor IX inhibitors, such as TTP889.

Original languageEnglish (US)
Pages (from-to)227-241
Number of pages15
JournalExpert Review of Hematology
Volume3
Issue number2
DOIs
StatePublished - Apr 2010

Keywords

  • Blood thinners
  • Deep vein thrombosis
  • Direct thrombin inhibitors
  • Factor Xa inhibitors
  • Heparin alternatives
  • Hip replacement prophylaxis
  • Knee replacement prophylaxis
  • Novel anticoagulants
  • Oral anticoagulants
  • Prophylaxis deep vein thrombosis

Fingerprint Dive into the research topics of 'Novel oral anticoagulants for prophylaxis and treatment of venous thromboembolism: Part i (Factor Xa inhibitors)'. Together they form a unique fingerprint.

Cite this